25 XP   0   0   10

Rocket Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Rocket Pharmaceuticals Inc together

PenkeI guess you are interested in Rocket Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Rocket Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Rocket Pharmaceuticals Inc

I send you an email if I find something interesting about Rocket Pharmaceuticals Inc.

Quick analysis of Rocket Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of Rocket Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
2.5%

What is your share worth?

Current worth
$5.44
Expected worth in 1 year
$5.47
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$0.03
Return On Investment
0.1%

For what price can you sell your share?

Current Price per Share
$21.98
Expected price per share
$16.55 - $28.73
How sure are you?
50%

1. Valuation of Rocket Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$21.98

Intrinsic Value Per Share

$-19.58 - $-11.94

Total Value Per Share

$-14.13 - $-6.50

2. Growth of Rocket Pharmaceuticals Inc (5 min.)




Is Rocket Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$492.5m$415.5m$58.2m12.3%

How much money is Rocket Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$60.5m-$54.8m-$5.7m-9.4%
Net Profit Margin-144.6%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Rocket Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#111 / 1010

Most Revenue
#417 / 1010

Most Profit
#915 / 1010

Most Efficient
#598 / 1010

What can you expect buying and holding a share of Rocket Pharmaceuticals Inc? (5 min.)

Welcome investor! Rocket Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Rocket Pharmaceuticals Inc.

What can you expect buying and holding a share of Rocket Pharmaceuticals Inc?

First you should know what it really means to hold a share of Rocket Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Rocket Pharmaceuticals Inc is $21.98. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Rocket Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Rocket Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.44. Based on the TTM, the Book Value Change Per Share is $0.01 per quarter. Based on the YOY, the Book Value Change Per Share is $0.10 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Rocket Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.66-3.0%-0.68-3.1%-0.61-2.8%-0.47-2.1%-0.30-1.4%
Usd Book Value Change Per Share-0.54-2.4%0.010.0%0.100.4%0.160.8%0.150.7%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.54-2.4%0.010.0%0.100.4%0.160.8%0.150.7%
Usd Price Per Share29.97-21.87-16.29-23.63-15.50-
Price to Earnings Ratio-11.37--8.09--6.74--14.30--16.21-
Price-to-Total Gains Ratio-55.91--31.24--34.17--55.98--61.61-
Price to Book Ratio5.51-4.19-3.55-5.65-6.18-
Price-to-Total Gains Ratio-55.91--31.24--34.17--55.98--61.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.98
Number of shares45
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.010.16
Usd Total Gains Per Share0.010.16
Gains per Quarter (45 shares)0.367.42
Gains per Year (45 shares)1.4429.69
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101-903020
203-805950
304-708980
406-60119110
507-50148140
609-40178170
7010-30208200
8011-20237230
9013-10267260
1001400297290

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.041.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%11.027.02.027.5%11.028.02.026.8%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.039.02.5%1.00.040.02.4%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%11.027.02.027.5%11.028.02.026.8%

Fundamentals of Rocket Pharmaceuticals Inc

About Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Fundamental data was last updated by Penke on 2024-04-12 16:19:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Rocket Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Rocket Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -578.5% means that $-5.79 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Rocket Pharmaceuticals Inc:

  • The MRQ is -578.5%. The company is making a huge loss. -2
  • The TTM is -144.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-578.5%TTM-144.6%-433.9%
TTM-144.6%YOY--144.6%
TTM-144.6%5Y-28.9%-115.7%
5Y-28.9%10Y-14.5%-14.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-578.5%-207.2%-371.3%
TTM-144.6%-216.8%+72.2%
YOY--282.3%+282.3%
5Y-28.9%-436.8%+407.9%
10Y-14.5%-597.3%+582.8%
1.1.2. Return on Assets

Shows how efficient Rocket Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • -10.5% Return on Assets means that Rocket Pharmaceuticals Inc generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Rocket Pharmaceuticals Inc:

  • The MRQ is -10.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.5%TTM-11.4%+0.9%
TTM-11.4%YOY-11.9%+0.4%
TTM-11.4%5Y-9.2%-2.3%
5Y-9.2%10Y-11.2%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.5%-13.3%+2.8%
TTM-11.4%-12.8%+1.4%
YOY-11.9%-11.6%-0.3%
5Y-9.2%-13.8%+4.6%
10Y-11.2%-15.6%+4.4%
1.1.3. Return on Equity

Shows how efficient Rocket Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • -12.1% Return on Equity means Rocket Pharmaceuticals Inc generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Rocket Pharmaceuticals Inc:

  • The MRQ is -12.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -13.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.1%TTM-13.0%+0.8%
TTM-13.0%YOY-13.3%+0.3%
TTM-13.0%5Y-10.8%-2.2%
5Y-10.8%10Y-10.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.1%-16.9%+4.8%
TTM-13.0%-16.1%+3.1%
YOY-13.3%-14.9%+1.6%
5Y-10.8%-19.3%+8.5%
10Y-10.8%-20.1%+9.3%

1.2. Operating Efficiency of Rocket Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Rocket Pharmaceuticals Inc is operating .

  • Measures how much profit Rocket Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of -574.0% means the company generated $-5.74  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Rocket Pharmaceuticals Inc:

  • The MRQ is -574.0%. The company is operating very inefficient. -2
  • The TTM is -143.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-574.0%TTM-143.5%-430.5%
TTM-143.5%YOY--143.5%
TTM-143.5%5Y-28.7%-114.8%
5Y-28.7%10Y-14.3%-14.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-574.0%-298.0%-276.0%
TTM-143.5%-238.5%+95.0%
YOY--288.4%+288.4%
5Y-28.7%-486.2%+457.5%
10Y-14.3%-628.4%+614.1%
1.2.2. Operating Ratio

Measures how efficient Rocket Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 6.64 means that the operating costs are $6.64 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Rocket Pharmaceuticals Inc:

  • The MRQ is 6.636. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.659. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.636TTM1.659+4.977
TTM1.659YOY-+1.659
TTM1.6595Y0.332+1.327
5Y0.33210Y0.166+0.166
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.6363.235+3.401
TTM1.6593.310-1.651
YOY-3.838-3.838
5Y0.3325.679-5.347
10Y0.1667.823-7.657

1.3. Liquidity of Rocket Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Rocket Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.80 means the company has $7.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Rocket Pharmaceuticals Inc:

  • The MRQ is 7.798. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.266. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.798TTM10.266-2.469
TTM10.266YOY12.173-1.907
TTM10.2665Y12.814-2.548
5Y12.81410Y15.455-2.642
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7983.863+3.935
TTM10.2664.169+6.097
YOY12.1735.337+6.836
5Y12.8146.122+6.692
10Y15.4556.434+9.021
1.3.2. Quick Ratio

Measures if Rocket Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 14.23 means the company can pay off $14.23 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Rocket Pharmaceuticals Inc:

  • The MRQ is 14.235. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 17.332. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ14.235TTM17.332-3.098
TTM17.332YOY18.019-0.687
TTM17.3325Y18.982-1.650
5Y18.98210Y22.053-3.071
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.2353.504+10.731
TTM17.3323.991+13.341
YOY18.0195.371+12.648
5Y18.9826.088+12.894
10Y22.0536.395+15.658

1.4. Solvency of Rocket Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Rocket Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Rocket Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.13 means that Rocket Pharmaceuticals Inc assets are financed with 13.0% credit (debt) and the remaining percentage (100% - 13.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Rocket Pharmaceuticals Inc:

  • The MRQ is 0.130. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.116. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.130TTM0.116+0.015
TTM0.116YOY0.107+0.009
TTM0.1165Y0.154-0.038
5Y0.15410Y0.680-0.526
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1300.339-0.209
TTM0.1160.337-0.221
YOY0.1070.271-0.164
5Y0.1540.368-0.214
10Y0.6800.388+0.292
1.4.2. Debt to Equity Ratio

Measures if Rocket Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 15.0% means that company has $0.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Rocket Pharmaceuticals Inc:

  • The MRQ is 0.150. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.131. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.150TTM0.131+0.019
TTM0.131YOY0.120+0.011
TTM0.1315Y0.189-0.058
5Y0.18910Y0.297-0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1500.392-0.242
TTM0.1310.403-0.272
YOY0.1200.335-0.215
5Y0.1890.427-0.238
10Y0.2970.461-0.164

2. Market Valuation of Rocket Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Rocket Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Rocket Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -11.37 means the investor is paying $-11.37 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Rocket Pharmaceuticals Inc:

  • The EOD is -8.336. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.366. Based on the earnings, the company is expensive. -2
  • The TTM is -8.086. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.336MRQ-11.366+3.030
MRQ-11.366TTM-8.086-3.280
TTM-8.086YOY-6.740-1.346
TTM-8.0865Y-14.301+6.215
5Y-14.30110Y-16.213+1.912
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.336-2.300-6.036
MRQ-11.366-2.656-8.710
TTM-8.086-2.718-5.368
YOY-6.740-4.145-2.595
5Y-14.301-6.258-8.043
10Y-16.213-6.315-9.898
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Rocket Pharmaceuticals Inc:

  • The EOD is -14.633. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -19.952. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.506. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.633MRQ-19.952+5.319
MRQ-19.952TTM-10.506-9.447
TTM-10.506YOY-7.937-2.569
TTM-10.5065Y-17.216+6.711
5Y-17.21610Y-19.275+2.059
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.633-2.974-11.659
MRQ-19.952-3.306-16.646
TTM-10.506-3.508-6.998
YOY-7.937-5.613-2.324
5Y-17.216-8.378-8.838
10Y-19.275-8.873-10.402
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Rocket Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.51 means the investor is paying $5.51 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Rocket Pharmaceuticals Inc:

  • The EOD is 4.039. Based on the equity, the company is fair priced.
  • The MRQ is 5.507. Based on the equity, the company is overpriced. -1
  • The TTM is 4.194. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.039MRQ5.507-1.468
MRQ5.507TTM4.194+1.313
TTM4.194YOY3.550+0.644
TTM4.1945Y5.653-1.459
5Y5.65310Y6.183-0.530
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0391.914+2.125
MRQ5.5072.116+3.391
TTM4.1942.097+2.097
YOY3.5502.881+0.669
5Y5.6533.550+2.103
10Y6.1833.936+2.247
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Rocket Pharmaceuticals Inc.

3.1. Institutions holding Rocket Pharmaceuticals Inc

Institutions are holding 100.952% of the shares of Rocket Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RTW INVESTMENTS, LLC19.54368.28041768777200
2023-12-31Wellington Management Company LLP9.05760.045881975461747162.1777
2023-12-31BlackRock Inc6.55240.0045593017881655115.9681
2023-12-31Vanguard Group Inc6.01910.0036544756584355218.3221
2023-12-31Maverick Capital Ltd4.45732.42794034068-1595902-28.3465
2023-12-31Westfield Capital Management Company, LP4.35540.68863941859-252137-6.0119
2023-12-31State Street Corporation3.57050.00473231411919062.9274
2023-09-30Citadel Advisors Llc2.95950.01182678501903933.4926
2023-12-31T. Rowe Price Associates, Inc.2.90490.01062629074-8877-0.3365
2023-12-31Avidity Partners Management LP1.89951.877617191031316748.2948
2023-12-31Perceptive Advisors LLC1.88651.1422170739818993112.5163
2023-12-31Boxer Capital LLC1.61992.1899146605100
2023-12-31Geode Capital Management, LLC1.61010.0046145725021709017.505
2023-12-31Pictet Asset Manangement SA1.48850.0445134716313471630
2023-12-31Logos Global Management LP1.40883.56681275000-700000-35.443
2023-12-31venBio Select Advisor LLC1.39320.5221260900109000.872
2023-12-31Goldman Sachs Group Inc1.31410.00321189330659611124.5209
2023-12-31COWEN AND COMPANY, LLC1.21542.1624110000000
2023-12-31Franklin Resources Inc1.18550.015107291040585560.8428
2023-12-31Putnam Investments LLC1.1820.04231069715704667.0519
Total 75.623823.048468442794+2492892+3.6%

3.2. Funds holding Rocket Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Health Care Inv4.52140.2642409205500
2024-03-28SPDR® S&P Biotech ETF3.02910.97812741473346001.2782
2024-02-29Vanguard Total Stock Mkt Idx Inv2.34160.0042119240-95091-4.2943
2024-03-28iShares Russell 2000 ETF1.70250.0634154085690630.5917
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.14240.02971033899580.0056
2024-02-29Vanguard Small Cap Index0.96260.018287116479060.9158
2023-12-31T. Rowe Price Health Sciences0.94410.1741854454-37791-4.2355
2023-12-31T. Rowe Price New Horizons0.94360.1035854016-2729-0.3185
2023-12-31US Small-Cap Growth II Equity Comp0.94360.1031854016-2729-0.3185
2023-12-31Putnam Global Health Care A0.88131.4927797600620008.4285
2023-12-31Westfield Capital Mgt Co Sm-Cap Gr Eq0.85181.8406770871-44964-5.5114
2024-01-31Harbor Small Cap Growth Instl0.83411.696754885-15986-2.0738
2023-12-31Baron Opportunity Retail0.82681.9841748270-51000-6.3808
2023-12-31Baron High Growth Strategy0.82681.983748270-51000-6.3808
2023-12-31Pictet-Biotech P USD0.80231.37767260897260890
2024-02-29Franklin Biotechnology Discv A(acc)USD0.76141.09468908800
2024-01-31Fidelity Small Cap Index0.70090.0735634314108851.746
2023-12-31HBM Healthcare Investments AG Ord0.69060.938262500000
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.68742.2563622162-9412-1.4902
2024-03-28iShares Biotechnology ETF0.68680.219462155600
Total 25.081116.693722699278+539899+2.4%

3.3. Insider Transactions

Insiders are holding 3.625% of the shares of Rocket Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08Mark Andrew WhiteSELL1253224.64
2024-03-21Gotham MakkerSELL27400028.43
2024-03-21John MilitelloSELL249028.1
2024-02-29John MilitelloSELL1000029.84
2024-02-29Martin WilsonSELL410029.33
2024-02-16Gaurav ShahSELL2027229.84
2024-02-16Kinnari PatelSELL713229.84
2024-02-16Martin WilsonSELL357629.84
2024-01-22John MilitelloSELL63827.2
2023-11-15Gotham MakkerSELL2000022.53
2023-10-20John MilitelloSELL56417.06
2023-09-28Gotham MakkerSELL1031221.03
2023-08-17Gaurav ShahSELL476715.47
2023-08-17Kinnari PatelSELL153415.47
2023-07-20John MilitelloSELL57319.03
2023-04-21John MilitelloSELL234218.65

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Rocket Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.5360.008-6819%0.097-655%0.165-425%0.147-465%
Book Value Per Share--5.4435.236+4%4.592+19%4.271+27%2.522+116%
Current Ratio--7.79810.266-24%12.173-36%12.814-39%15.455-50%
Debt To Asset Ratio--0.1300.116+13%0.107+22%0.154-15%0.680-81%
Debt To Equity Ratio--0.1500.131+14%0.120+25%0.189-21%0.297-50%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.659-0.678+3%-0.613-7%-0.472-28%-0.298-55%
Free Cash Flow Per Share---0.376-0.584+55%-0.516+37%-0.397+6%-0.239-36%
Free Cash Flow To Equity Per Share---0.371-0.008-98%-0.087-77%0.121-408%0.119-412%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---11.941--------
Intrinsic Value_10Y_min---19.576--------
Intrinsic Value_1Y_max---0.992--------
Intrinsic Value_1Y_min---1.957--------
Intrinsic Value_3Y_max---3.137--------
Intrinsic Value_3Y_min---5.919--------
Intrinsic Value_5Y_max---5.470--------
Intrinsic Value_5Y_min---9.893--------
Market Cap1989282316.000-36%2712410874.0001978874333.000+37%1474087157.500+84%2138252229.200+27%1403041360.500+93%
Net Profit Margin---5.785-1.446-75%--100%-0.289-95%-0.145-98%
Operating Margin---5.740-1.435-75%--100%-0.287-95%-0.143-98%
Operating Ratio--6.6361.659+300%-+100%0.332+1900%0.166+3900%
Pb Ratio4.039-36%5.5074.194+31%3.550+55%5.653-3%6.183-11%
Pe Ratio-8.336+27%-11.366-8.086-29%-6.740-41%-14.301+26%-16.213+43%
Price Per Share21.980-36%29.97021.865+37%16.288+84%23.626+27%15.503+93%
Price To Free Cash Flow Ratio-14.633+27%-19.952-10.506-47%-7.937-60%-17.216-14%-19.275-3%
Price To Total Gains Ratio-41.006+27%-55.912-31.243-44%-34.175-39%-55.976+0%-61.614+10%
Quick Ratio--14.23517.332-18%18.019-21%18.982-25%22.053-35%
Return On Assets---0.105-0.114+9%-0.119+12%-0.092-13%-0.112+6%
Return On Equity---0.121-0.130+7%-0.133+10%-0.108-11%-0.108-11%
Total Gains Per Share---0.5360.008-6819%0.097-654%0.165-425%0.147-465%
Usd Book Value--492574000.000473876500.000+4%415578750.000+19%386518450.000+27%228227075.000+116%
Usd Book Value Change Per Share---0.5360.008-6819%0.097-655%0.165-425%0.147-465%
Usd Book Value Per Share--5.4435.236+4%4.592+19%4.271+27%2.522+116%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.659-0.678+3%-0.613-7%-0.472-28%-0.298-55%
Usd Free Cash Flow---33986000.000-52847000.000+55%-46690250.000+37%-35932900.000+6%-21634375.000-36%
Usd Free Cash Flow Per Share---0.376-0.584+55%-0.516+37%-0.397+6%-0.239-36%
Usd Free Cash Flow To Equity Per Share---0.371-0.008-98%-0.087-77%0.121-408%0.119-412%
Usd Market Cap1989282316.000-36%2712410874.0001978874333.000+37%1474087157.500+84%2138252229.200+27%1403041360.500+93%
Usd Price Per Share21.980-36%29.97021.865+37%16.288+84%23.626+27%15.503+93%
Usd Profit---59660000.000-60551000.000+1%-54845750.000-8%-42381300.000-29%-26800200.000-55%
Usd Revenue--10312000.0002578000.000+300%-+100%515600.000+1900%257800.000+3900%
Usd Total Gains Per Share---0.5360.008-6819%0.097-654%0.165-425%0.147-465%
 EOD+3 -5MRQTTM+17 -16YOY+14 -215Y+15 -2010Y+13 -22

4.2. Fundamental Score

Let's check the fundamental score of Rocket Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.336
Price to Book Ratio (EOD)Between0-14.039
Net Profit Margin (MRQ)Greater than0-5.785
Operating Margin (MRQ)Greater than0-5.740
Quick Ratio (MRQ)Greater than114.235
Current Ratio (MRQ)Greater than17.798
Debt to Asset Ratio (MRQ)Less than10.130
Debt to Equity Ratio (MRQ)Less than10.150
Return on Equity (MRQ)Greater than0.15-0.121
Return on Assets (MRQ)Greater than0.05-0.105
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Rocket Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.430
Ma 20Greater thanMa 5024.247
Ma 50Greater thanMa 10026.609
Ma 100Greater thanMa 20027.459
OpenGreater thanClose22.160
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -357267-90-632-722214-508827319
Gross Profit  -1,778105-1,673-49-1,722-39-1,7616,9175,156



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets566,341
Total Liabilities73,767
Total Stockholder Equity492,574
 As reported
Total Liabilities 73,767
Total Stockholder Equity+ 492,574
Total Assets = 566,341

Assets

Total Assets566,341
Total Current Assets378,222
Long-term Assets188,119
Total Current Assets
Cash And Cash Equivalents 55,904
Short-term Investments 317,271
Other Current Assets 5,047
Total Current Assets  (as reported)378,222
Total Current Assets  (calculated)378,222
+/-0
Long-term Assets
Property Plant Equipment 87,590
Goodwill 39,154
Long Term Investments 34,320
Intangible Assets 25,150
Long-term Assets Other 1,372
Long-term Assets  (as reported)188,119
Long-term Assets  (calculated)187,586
+/- 533

Liabilities & Shareholders' Equity

Total Current Liabilities48,505
Long-term Liabilities25,262
Total Stockholder Equity492,574
Total Current Liabilities
Short-term Debt 2,716
Other Current Liabilities 45,789
Total Current Liabilities  (as reported)48,505
Total Current Liabilities  (calculated)48,505
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt22,326
Long-term Liabilities Other 2,936
Long-term Liabilities  (as reported)25,262
Long-term Liabilities  (calculated)25,262
+/-0
Total Stockholder Equity
Common Stock903
Retained Earnings -959,370
Accumulated Other Comprehensive Income 319
Other Stockholders Equity 1,450,722
Total Stockholder Equity (as reported)492,574
Total Stockholder Equity (calculated)492,574
+/-0
Other
Capital Stock903
Cash and Short Term Investments 373,175
Common Stock Shares Outstanding 84,009
Liabilities and Stockholders Equity 566,341
Net Debt -30,862
Net Invested Capital 492,574
Net Working Capital 329,717
Property Plant and Equipment Gross 101,622
Short Long Term Debt Total 25,042



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
12,863
0
0
8,498
5,520
55,526
51,688
120,124
113,321
104,207
99,851
140,139
129,647
117,923
111,065
104,655
101,778
217,165
207,574
194,981
251,313
242,138
308,720
299,910
372,121
372,751
353,065
335,496
590,824
576,484
535,154
530,241
497,020
460,150
431,852
417,265
551,807
514,757
461,781
598,762
566,341
566,341598,762461,781514,757551,807417,265431,852460,150497,020530,241535,154576,484590,824335,496353,065372,751372,121299,910308,720242,138251,313194,981207,574217,165101,778104,655111,065117,923129,647140,13999,851104,207113,321120,12451,68855,5265,5208,4980012,863
   > Total Current Assets 
12,859
0
0
7,431
3,670
53,440
49,477
119,224
112,366
103,247
98,702
138,924
128,349
116,633
109,821
103,872
101,047
184,828
134,608
128,821
209,088
199,619
263,629
245,591
307,754
279,805
255,436
233,214
487,345
471,822
430,426
425,069
392,059
353,848
325,771
311,131
364,060
338,033
312,074
446,865
378,222
378,222446,865312,074338,033364,060311,131325,771353,848392,059425,069430,426471,822487,345233,214255,436279,805307,754245,591263,629199,619209,088128,821134,608184,828101,047103,872109,821116,633128,349138,92498,702103,247112,366119,22449,47753,4403,6707,4310012,859
       Cash And Cash Equivalents 
12,793
0
0
7,357
3,618
53,139
49,012
89,248
80,042
58,706
38,519
83,004
29,798
25,273
27,610
49,146
78,720
171,136
52,548
38,076
111,355
124,464
64,833
89,195
185,383
190,520
163,203
82,226
297,098
252,540
264,608
245,644
232,694
130,552
187,548
196,669
140,517
64,579
45,076
225,657
55,904
55,904225,65745,07664,579140,517196,669187,548130,552232,694245,644264,608252,540297,09882,226163,203190,520185,38389,19564,833124,464111,35538,07652,548171,13678,72049,14627,61025,27329,79883,00438,51958,70680,04289,24849,01253,1393,6187,3570012,793
       Short-term Investments 
0
0
0
0
0
0
0
29,117
31,238
43,559
59,703
54,579
96,675
89,432
81,144
53,979
21,294
11,561
79,555
89,402
94,375
72,126
192,950
151,366
118,732
85,375
86,600
146,464
185,621
213,813
162,222
175,815
156,046
216,041
133,820
109,865
215,877
266,505
261,964
211,514
317,271
317,271211,514261,964266,505215,877109,865133,820216,041156,046175,815162,222213,813185,621146,46486,60085,375118,732151,366192,95072,12694,37589,40279,55511,56121,29453,97981,14489,43296,67554,57959,70343,55931,23829,1170000000
       Other Current Assets 
66
0
0
74
52
301
465
859
1,086
982
480
1,341
1,876
1,928
1,067
747
1,033
2,131
2,505
1,343
3,358
3,029
5,846
5,030
3,639
3,910
5,633
4,524
4,626
5,469
3,596
3,610
3,319
7,255
4,403
4,597
7,666
6,949
5,034
9,694
5,047
5,0479,6945,0346,9497,6664,5974,4037,2553,3193,6103,5965,4694,6264,5245,6333,9103,6395,0305,8463,0293,3581,3432,5052,1311,0337471,0671,9281,8761,3414809821,08685946530152740066
   > Long-term Assets 
4
0
0
1,067
1,850
2,086
2,211
900
955
960
1,149
1,215
1,298
1,290
1,244
783
731
32,337
72,966
66,160
42,225
42,519
45,091
54,319
64,367
92,946
97,629
102,282
103,479
104,662
104,728
105,172
104,961
106,300
106,081
106,134
187,747
176,724
149,707
151,897
188,119
188,119151,897149,707176,724187,747106,134106,081106,300104,961105,172104,728104,662103,479102,28297,62992,94664,36754,31945,09142,51942,22566,16072,96632,3377317831,2441,2901,2981,2151,1499609559002,2112,0861,8501,067004
       Property Plant Equipment 
0
0
0
0
0
0
29
756
812
790
976
1,045
1,130
1,122
1,076
601
563
1,146
976
1,245
2,027
9,724
12,296
21,524
31,346
60,151
64,834
69,444
70,641
71,931
72,124
72,568
72,348
73,687
73,468
73,510
77,645
81,090
82,925
85,679
87,590
87,59085,67982,92581,09077,64573,51073,46873,68772,34872,56872,12471,93170,64169,44464,83460,15131,34621,52412,2969,7242,0271,2459761,1465636011,0761,1221,1301,04597679081275629000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
30,815
39,154
39,154
39,154
39,154
39,154
39,15439,15439,15439,15439,15430,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81530,81500000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,363
32,000
7,402
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
43,276
28,957
0
0
34,320
34,3200028,95743,2760000000000000007,40232,00039,363000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,815
30,815
30,815
0
0
0
0
226
226
0
0
0
0
0
0
0
0
0
0
25,724
25,724
25,724
25,150
25,150
25,15025,15025,72425,72425,7240000000000226226000030,81530,81530,81500000000000000000
       Long-term Assets Other 
4
0
0
1,067
1,850
2,086
2,182
144
143
170
173
170
168
168
168
182
168
376
1,644
1,645
1,436
1,980
1,980
1,980
1,980
1,980
1,980
2,023
2,023
1,916
1,789
1,789
1,798
1,798
1,798
1,809
1,948
1,799
1,904
1,914
1,372
1,3721,9141,9041,7991,9481,8091,7981,7981,7981,7891,7891,9162,0232,0231,9801,9801,9801,9801,9801,9801,4361,6451,6443761681821681681681701731701431442,1822,0861,8501,067004
> Total Liabilities 
51,758
0
0
8,814
57,079
21,574
19,969
3,649
4,508
4,965
4,407
55,085
56,479
54,659
53,535
53,580
54,014
47,019
50,498
51,361
57,276
65,061
60,216
67,992
64,824
86,700
86,542
93,655
87,305
96,485
45,717
44,583
42,296
42,530
44,156
49,952
62,121
55,881
58,811
57,676
73,767
73,76757,67658,81155,88162,12149,95244,15642,53042,29644,58345,71796,48587,30593,65586,54286,70064,82467,99260,21665,06157,27651,36150,49847,01954,01453,58053,53554,65956,47955,0854,4074,9654,5083,64919,96921,57457,0798,8140051,758
   > Total Current Liabilities 
3,218
0
0
5,496
7,222
2,457
2,452
3,243
4,141
4,614
4,071
5,944
7,212
5,268
4,016
3,767
4,070
7,337
10,146
10,294
15,372
20,572
15,081
22,181
18,309
21,114
20,685
31,955
32,617
40,492
25,444
24,489
22,167
22,570
24,289
30,181
39,169
31,206
34,346
33,476
48,505
48,50533,47634,34631,20639,16930,18124,28922,57022,16724,48925,44440,49232,61731,95520,68521,11418,30922,18115,08120,57215,37210,29410,1467,3374,0703,7674,0165,2687,2125,9444,0714,6144,1413,2432,4522,4577,2225,496003,218
       Short-term Debt 
1,410
0
0
2,980
4,604
0
0
0
1,721
0
0
0
4,834
2,485
2,898
2,784
0
39,084
39,842
0
0
892
913
935
957
2,295
2,440
7,125
7,145
7,324
7,560
2,481
2,552
2,539
2,449
2,358
2,509
2,597
2,993
2,852
2,716
2,7162,8522,9932,5972,5092,3582,4492,5392,5522,4817,5607,3247,1457,1252,4402,2959579359138920039,84239,08402,7842,8982,4854,8340001,7210004,6042,980001,410
       Short Long Term Debt 
0
0
0
0
0
0
0
0
14
0
0
0
0
0
0
0
0
39,084
39,842
0
0
892
0
0
0
0
0
4,765
4,875
4,986
5,102
0
0
0
0
0
0
0
0
0
0
00000000005,1024,9864,8754,765000008920039,84239,084000000001400000000
       Accounts payable 
229
0
0
1,048
1,146
1,301
813
1,709
1,633
1,376
921
1,777
1,592
1,902
368
383
451
67
66
9,765
15,372
18,247
-913
-935
-957
-2,295
-2,440
24,830
25,472
33,168
17,884
22,008
482
20,031
21,840
2
36,660
2
1
2
0
021236,660221,84020,03148222,00817,88433,16825,47224,830-2,440-2,295-957-935-91318,24715,3729,76566674513833681,9021,5921,7779211,3761,6331,7098131,3011,1461,04800229
       Other Current Liabilities 
1,185
0
0
1,053
1,051
727
1,203
1,091
337
2,781
2,686
3,696
308
396
258
101
3,113
6,757
9,560
9,767
14,838
892
14,533
21,626
17,747
20,545
20,109
-583
-590
32,571
17,884
22,008
19,615
20,031
21,840
27,823
37,433
28,609
31,353
30,624
45,789
45,78930,62431,35328,60937,43327,82321,84020,03119,61522,00817,88432,571-590-58320,10920,54517,74721,62614,53389214,8389,7679,5606,7573,1131012583963083,6962,6862,7813371,0911,2037271,0511,053001,185
   > Long-term Liabilities 
48,540
0
0
3,318
49,857
19,117
17,517
406
367
351
336
49,141
49,267
49,391
49,519
49,813
49,944
39,682
40,352
41,067
41,904
44,489
45,135
45,811
46,515
65,586
65,857
61,700
54,688
55,993
20,273
20,094
20,129
19,960
19,867
19,771
22,952
24,675
24,465
24,200
25,262
25,26224,20024,46524,67522,95219,77119,86719,96020,12920,09420,27355,99354,68861,70065,85765,58646,51545,81145,13544,48941,90441,06740,35239,68249,94449,81349,51949,39149,26749,14133635136740617,51719,11749,8573,3180048,540
       Long term Debt Total 
0
0
0
0
0
8,667
8,926
0
0
0
0
48,820
48,960
49,099
49,242
49,390
49,541
39,084
39,842
40,629
41,447
42,297
43,180
44,097
45,049
45,794
46,228
42,132
35,066
35,544
0
0
0
0
0
0
0
0
0
0
0
0000000000035,54435,06642,13246,22845,79445,04944,09743,18042,29741,44740,62939,84239,08449,54149,39049,24249,09948,96048,82000008,9268,66700000
       Other Liabilities 
0
0
0
0
0
0
0
0
367
0
0
0
107
292
277
108
107
598
510
438
457
23
22
23
23
23
23
23
136
122
107
94
80
65
51
37
2,595
0
2,072
0
0
002,07202,59537516580941071221362323232323222345743851059810710827729210700036700000000
       Deferred Long Term Liability 
0
0
0
0
0
10,426
8,567
0
0
0
0
0
0
0
0
0
0
598
510
438
457
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000045743851059800000000008,56710,42600000
> Total Stockholder Equity
-38,895
0
0
-316
-51,559
33,952
31,719
116,475
108,813
99,242
95,444
85,054
73,168
63,264
57,530
51,075
47,764
170,146
157,076
143,620
194,037
177,077
248,504
231,918
307,297
286,051
266,523
241,841
503,519
479,999
489,437
485,658
454,724
417,620
387,696
367,313
489,686
458,876
402,970
541,086
492,574
492,574541,086402,970458,876489,686367,313387,696417,620454,724485,658489,437479,999503,519241,841266,523286,051307,297231,918248,504177,077194,037143,620157,076170,14647,76451,07557,53063,26473,16885,05495,44499,242108,813116,47531,71933,952-51,559-31600-38,895
   Common Stock
10
0
0
92
10
163
163
264
264
264
269
269
270
270
270
272
68
394
395
398
452
451
503
503
548
551
551
552
610
619
634
644
645
645
658
678
791
804
805
901
903
9039018058047916786586456456446346196105525515515485035034514523983953946827227027027026926926426426416316310920010
   Retained Earnings -959,370-899,710-837,811-772,110-713,775-647,052-589,296-534,894-491,912-447,665-397,547-363,022-322,843-261,927-232,847-207,807-183,143-163,288-144,004-125,324-105,873-78,554-62,465-46,698-268,374-263,504-256,109-249,547-238,877-225,903-214,775-206,091-196,023-187,851-131,890-129,503-128,041-125,89300-118,510
   Capital Surplus 
0
0
0
0
0
163,292
163,446
304,062
304,583
305,069
309,933
310,686
311,829
312,613
313,441
314,332
316,086
216,440
219,225
221,983
300,253
302,039
392,205
394,930
489,925
493,811
498,590
503,223
825,794
842,477
886,431
932,776
946,152
952,498
977,099
1,014,283
0
1,230,319
1,240,745
0
0
001,240,7451,230,31901,014,283977,099952,498946,152932,776886,431842,477825,794503,223498,590493,811489,925394,930392,205302,039300,253221,983219,225216,440316,086314,332313,441312,613311,829310,686309,933305,069304,583304,062163,446163,29200000
   Treasury Stock000-4700000000000-429-53-344-3440-66800000000000000000000
   Other Stockholders Equity 
38,589
0
0
125,702
29,888
163,292
111,759
183,945
304,834
305,368
310,284
311,061
312,206
312,816
313,707
314,604
316,405
216,803
219,544
222,161
299,937
302,531
392,688
395,507
490,797
494,330
499,960
504,636
825,794
842,477
886,431
932,776
946,152
952,498
977,099
1,014,283
1,203,027
1,230,272
1,240,698
1,440,403
1,450,722
1,450,7221,440,4031,240,6981,230,2721,203,0271,014,283977,099952,498946,152932,776886,431842,477825,794504,636499,960494,330490,797395,507392,688302,531299,937222,161219,544216,803316,405314,604313,707312,816312,206311,061310,284305,368304,834183,945111,759163,29229,888125,7020038,589



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-7,098
Gross Profit-7,098-7,098
 
Operating Income (+$)
Gross Profit-7,098
Operating Expense-252,561
Operating Income-259,659-259,659
 
Operating Expense (+$)
Research Development180,967
Selling General Administrative73,317
Selling And Marketing Expenses1,723
Operating Expense252,561256,007
 
Net Interest Income (+$)
Interest Income13,095
Interest Expense-1,875
Other Finance Cost-1,084
Net Interest Income12,304
 
Pretax Income (+$)
Operating Income-259,659
Net Interest Income12,304
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-245,595-273,723
EBIT - interestExpense = -261,534
-245,595
-243,720
Interest Expense1,875
Earnings Before Interest and Taxes (EBIT)-259,659-243,720
Earnings Before Interest and Taxes (EBITDA)-252,561
 
After tax Income (+$)
Income Before Tax-245,595
Tax Provision-0
Net Income From Continuing Ops-252,658-245,595
Net Income-245,595
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses259,659
Total Other Income/Expenses Net14,064-12,304
 

Technical Analysis of Rocket Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Rocket Pharmaceuticals Inc. The general trend of Rocket Pharmaceuticals Inc is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Rocket Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Rocket Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 25.55 < 25.66 < 28.73.

The bearish price targets are: 21.46 > 17.85 > 16.55.

Tweet this
Rocket Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Rocket Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Rocket Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Rocket Pharmaceuticals Inc. The current macd is -1.13133173.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rocket Pharmaceuticals Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Rocket Pharmaceuticals Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Rocket Pharmaceuticals Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Rocket Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartRocket Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Rocket Pharmaceuticals Inc. The current adx is 21.39.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Rocket Pharmaceuticals Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Rocket Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Rocket Pharmaceuticals Inc. The current sar is 24.70.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Rocket Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Rocket Pharmaceuticals Inc. The current rsi is 31.43. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Rocket Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartRocket Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Rocket Pharmaceuticals Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Rocket Pharmaceuticals Inc price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Rocket Pharmaceuticals Inc Daily Stochastic Oscillator ChartRocket Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Rocket Pharmaceuticals Inc. The current cci is -178.30773896.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Rocket Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartRocket Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Rocket Pharmaceuticals Inc. The current cmo is -44.06539303.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Rocket Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartRocket Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Rocket Pharmaceuticals Inc. The current willr is -92.60949615.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Rocket Pharmaceuticals Inc Daily Williams %R ChartRocket Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Rocket Pharmaceuticals Inc. The current atr is 1.10899771.

Rocket Pharmaceuticals Inc Daily Average True Range (ATR) ChartRocket Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Rocket Pharmaceuticals Inc. The current obv is 21,638,930.

Rocket Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartRocket Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Rocket Pharmaceuticals Inc. The current mfi is 31.55.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Rocket Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartRocket Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Rocket Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Rocket Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Rocket Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.430
Ma 20Greater thanMa 5024.247
Ma 50Greater thanMa 10026.609
Ma 100Greater thanMa 20027.459
OpenGreater thanClose22.160
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Rocket Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Rocket Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Rocket Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Rocket Pharmaceuticals Inc

I send you an email if I find something interesting about Rocket Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Rocket Pharmaceuticals Inc.

Receive notifications about Rocket Pharmaceuticals Inc in your mailbox!